Rock Creek Pharmaceuticals, Inc. (RCPIQ)

Overview

Rock Creek Pharmaceuticals, Inc., previously recognized as Star Scientific, Inc. before its rebranding in June 2014, was a pharmaceutical development company that focused on the discovery, advancement, and market launch of therapeutic solutions aimed at treating chronic inflammatory diseases and neurological disorders. The firm was situated in Sarasota, Florida, and operated with a commitment to innovate in the field of medicine. Its notable drug candidate, Anatabine citrate, represents a significant advancement in anti-inflammatory treatment with its distinct mechanism of action that sets it apart from traditional medications.

The operational approach of Rock Creek Pharmaceuticals was to explore new avenues for therapeutic interventions, especially in areas where existing treatments had limitations. However, the journey of the company came to a halt when it formally filed for Chapter 7 liquidation on September 27, 2016, in the US Bankruptcy Court for the District of Delaware, closing a chapter in its quest to bring new medical solutions to market.

Products and Services

• Anatabine Citrate - This small-molecule cholinergic agonist is the flagship drug candidate of Rock Creek Pharmaceuticals. Anatabine citrate exhibits unique anti-inflammatory properties that differentiate it from other typical anti-inflammatory therapeutics. Its mechanism of action is notably distinct from that of biologics, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs), potentially offering new hope for patients suffering from chronic inflammatory conditions.